SYNJ2BP-COX16

Across TCGA pan-cancer cohorts, SYNJ2BP-COX16 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated SYNJ2BP-COX16 data layer compared with 1 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SYNJ2BP-COX16 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SYNJ2BP-COX16 expression acts as an unfavorable survival marker, although some lineages such as CHOL and KIRC show a favorable association.

ACC, MESO, and UCEC are the cancer types where SYNJ2BP-COX16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Tertile	All	0.315	0.718	<.001	66	view →
MESO	OS	Median	All	0.289	0.471	.004	26	view →
UCEC	DFS	Quartile	All	0.776	0.887	.003	20	view →
LUAD	DFS	Tertile	All	0.275	0.494	.010	19	view →
CHOL	OS	Tertile	All	0.818	0.142	.023	18	view →
DLBC	DFS	Tertile	IV	0.184	0.923	.006	17	view →
KICH	DFS	Median	II,III,IV	0.606	0.915	.015	16	view →
THCA	OS	Median	All	0.963	1.000	.015	11	view →
KIRC	DFS	Median	All	0.857	0.731	.010	9	view →
LGG	OS	Tertile	All	0.829	0.948	.022	4	view →
KIRP	DFS	Tertile	All	1.000	0.747	.043	4	view →
SCLC	OS	Tertile	All	0.597	0.762	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

SYNJ2BP-COX16–ACC (DFS)

Open the ACC breakdown →